DU Knib 250mg Tablet contains Lapatinib as an active ingredient, which is used in combination with capecitabine for treating patients with HER2-positive advanced or metastatic breast cancer who have received prior treatment. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.

FAQs

How does DU Knib 250mg Tablet work?

DU Knib 250mg Tablet contains Lapatinib, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth.

What are the points to be informed to the doctor before starting treatment?

Inform your doctor whether you have received any other breast cancer treatment. DU Knib 250mg Tablet may cause left ventricular ejection fraction, hypersensitivity reactions, hepatotoxicity, severe diarrhea, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, are pregnant, are planning to become pregnant, or are breastfeeding before taking DU Knib 250mg Tablet.

Does DU Knib 250mg Tablet cause liver problems?

Hepatotoxicity (liver toxicity) has been reported in clinical studies and postmarketing experience with DU Knib 250mg Tablet. Hepatotoxicity can be fatal, and deaths have been reported. The cause of death is unknown. If you have upper stomach pain, itching, dark urine, clay-coloured faeces, or jaundice (yellowing of the skin or eyes), inform your doctor immediately.